Hjem › Immunsystem og lidelser › Massachusetts › Boston
Immunsystem og lidelser kliniske forsøg i Boston, MA
10 studier for Immunsystem og lidelser søger deltagere på steder i og omkring Boston (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.
Officiel studietekst (engelsk)
Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
RekruttererFase 1
- Beth Israel Deaconess Medical Center - Research, Boston
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RekruttererFase 3
- Massachusetts General Hospital, Boston
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
RekruttererObservationsstudie
- Brigham and Women's Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
RekruttererFase 2
- Dana-Farber Cancer Institute, Boston
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RekruttererFase 3
- Massachusetts General Hospital, Boston
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
RekruttererFase 1
- Massachusetts General Hospital, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RekruttererFase 1/2
- Massachusetts General Hospital, Boston
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
RekruttererFase 1/2
- Brigham and Women's Hospital, Boston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
RekruttererFase 1/2
- Dana Farber Cancer Institute, Boston
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
RekruttererFase 2
- Dana-Farber Cancer Institute, Boston
Immunsystem og lidelser forsøg i andre byer
- Washington, DC13 studier
- New York City, NY12 studier
- Philadelphia, PA10 studier
- Atlanta, GA9 studier
- Portland, OR9 studier
- Houston, TX9 studier
- Cleveland, OH8 studier
- Chicago, IL8 studier
- Los Angeles, CA8 studier
- Milwaukee, WI6 studier
- Seattle, WA6 studier
- Cedar Rapids, IA6 studier
Andre studier i Boston
- Brystkræft111 studier
- Ikke-småcellet lungecancer90 studier
- Kræft (alle typer)86 studier
- Colorektal kræft63 studier
- Metastatisk cancer63 studier
- Lungecancer62 studier
- Ægstockræft61 studier
- Prostatakræft59 studier
- Depression52 studier
- Livmoderslimhindekræft50 studier
- Hjertesvigt44 studier
- Akut myeloid leukæmi44 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.